Key points from article :
Researchers at the Chan Zuckerberg Biohub Chicago have achieved a groundbreaking milestone in real-time health monitoring by developing implantable sensors that can continuously track protein levels linked to inflammation. These sensors, tested in diabetic rats, measure cytokine proteins—key markers of inflammation—by using a unique nanoscale design that "shakes" captured proteins off for real-time analysis. This innovation, published in Science on December 5, 2024, opens the door to a deeper understanding of inflammation, which is linked to 50% of all deaths globally due to conditions like cancer and heart disease.
The sensors work by embedding DNA-based "pendulums" into microneedles, which are implanted under the skin. These devices measure subtle changes in protein levels, such as those caused by immune system activation or diabetes management. In tests, the sensors successfully recorded inflammation levels fluctuating in response to different conditions, demonstrating their potential to revolutionize how inflammation-related illnesses are monitored and treated.
Looking ahead, the team aims to refine the technology for human use, enabling continuous inflammation tracking similar to how glucose monitors transformed diabetes care. This could pave the way for earlier interventions, better disease prevention, and significant advancements in healthcare. Dr. Shana Kelley, President of CZ Biohub Chicago, envisions the technology as a game-changer, with limitless possibilities for improving health by keeping inflammation under control.
